Resources & Guides

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

Retatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.

Retatrutide is not FDA-approved. It's currently in Phase 3 clinical trials (TRIUMPH program) with expected approval in 2027. Here's everything you need to know about its regulatory status, trial progress, and how to access it today.

A dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.

Retatrutide is not commercially available. Phase 3 results have been reported and Lilly plans a BLA filing in Q1 2027, with approval possible in 2027-2028. In the US, lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). Compounding pharmacies cannot lawfully supply it. Here is everything you need to know about retatrutide availability worldwide.

How much weight can you lose on semaglutide? STEP 1 trial data shows 14.9% mean body weight loss at 68 weeks, with 86.4% of participants losing at least 5%. This guide breaks down the clinical evidence, month-by-month timeline, real-world results, and what factors determine your outcome.

Retatrutide isn't FDA-approved yet. Lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). This guide covers how to join a trial, who qualifies for expanded access, why compounding pharmacies cannot lawfully supply retatrutide, and what research peptide vendors actually sell, plus what you need to know about safety, legality, and costs.